Please login to the form below

Not currently logged in
Email:
Password:

GSK/Neurocrine depression drug fails

A potential therapy for depression developed by GlaxoSmithKline and Neurocrine Biosciences failed to meet its goal in a mid-stage clinical trial

A potential new therapy for major depression that is being developed through a partnership between GlaxoSmithKline (GSK) and Neurocrine Biosciences failed to meet its goal in a mid-stage clinical trial.

Top-line efficacy and safety results from a phase II trial of Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 found that the drug was no more effective than placebo in patients experiencing a major depressive episode.

The study, which was conducted by GSK, enrolled 150 patients who were randomised to receive either 350mg of GSK561679 daily or placebo. The primary endpoint was change from baseline in the Bech Melancholia scale at week six. The Bech Melancholia scale is designed to measure the severity of depressive symptoms in patients with depressive illness.

Neurocrine said it will meet with GSK once the full clinical data set is complete, which is targeted for within the next few months, to decide on the next steps for the development programme. Meanwhile, clinical trials are ongoing to test the drug as a treatment for post traumatic stress disorder, anxiety and alcoholism.

Neurocrine and GSK signed a worldwide research, development and commercialisation agreement for Corticotropin Releasing Factor Receptor Antagonists for psychiatric, neurological and gastrointestinal diseases in 2001.

15th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics